Successful cryopreservation of gonadal tissue is an important factor in guaranteeing the fertility preservation via germ cell or testicular tissue transplantation. The aim of this study was to evaluate the effects of cooling and cryopreservation on spermatogonial stem cell survival and function of immature non-human primate testicular tissue xenografted to nude mice. Group 1 (control group) received subcutaneous grafts of fresh immature rhesus monkey testes. The treatment groups received grafts after 24 h cooling in ice-cold medium (Group 2), after 24 h of cryopreservation without cryoprotectant (Group 3), with ethylene glycol (Group 4: 1.4 M) or with dimethylsulphoxide (DMSO) (group 5: 1.4 M; group 6: 0.7 M), using cooling rates of 0.5°C/min. The graft number, weight and histology were examined 3–5 months later. After xenografting, grafts from fresh and cooled tissue showed good survival and spermatogenic induction to spermatocytes. Cryopreservation in 1.4 M DMSO also allowed grafts to initiate spermatogenesis. In contrast, 0.7 M DMSO and ethylene glycol showed inferior protection. Our observations suggest that cryopreservation of immature primate testis is a feasible approach to maintain spermatogonial stem cells and may serve as a promising tool for fertility preservation of prepubertal boys. The possibility to delay the transplantation of cooled samples suggests an option for clinical centralization of testicular tissue cryopreservation.
Male gonadal dysfunction is a frequent late effect after pediatric hematopoietic stem cell transplantation (HSCT), but detailed insights into patterns of male gonadal function at long-term is limited since studies have been retrospective without semen sample data. We investigated 1) the risk of azoospermia and testosterone deficiency, 2) the diagnostic value of markers of spermatogenesis, and 3) paternity at long-term follow-up after pediatric allogeneic HSCT. All surviving men ≥18 years of age transplanted in Denmark or Finland between 1980-2010 were invited to this cross-sectional study. Examinations included a semen sample, reproductive hormones, testicular volumes and screening for chronic graft-versus-host-disease (GvHD). Cumulative (pre-HSCT plus HSCT) treatment doses were calculated. Of 181 eligible patients, 98 participated median (range) 18 (8-35) years after HSCT. Sperm was found in 30 patients, azoospermia in 42, and azoospermia during testosterone substitution in 24 patients. A higher cumulative testicular irradiation dose was associated with increased risk of azoospermia and testosterone substitution (odds ratio [OR] per +1 Gy 1.27, 95%CI 1.14-1.46); p12 Gy had azoospermia and all but one treated with >16 Gy needed testosterone substitution. In patients treated with chemotherapy only (n=23), a higher cumulative cyclophosphamide equivalent dose was associated with increased the risk of azoospermia (OR per +1 g/m2 1.34, 95%CI 1.01-2.15; p=0.037). Pre-pubertal stage at HSCT was a risk factor for testosterone substitution (OR 15.31, 95%CI 2.39-315; p=0.017), while chronic GvHD was unrelated to gonadal dysfunction. Inhibin B was the best surrogate marker of azoospermia (area under the curve 0.91, 95%CI 0.85-0.98, 90% sensitivity and 83% specificity) compared to follicle-stimulating hormone and testicular volume. Of 24 males who had attempted to conceive, six had fathered children. In conclusion, the risk of male gonadal dysfunction after pediatric HSCT is high and depends primarily on the cumulative testicular irradiation dose and pubertal stage at transplant. Our findings pinpoint the need of fertility preservation before HSCT as well as prolonged follow-up of pediatric HSCT patients into adulthood.
1 December 2012 in The Journal of Clinical Endocrinology & Metabolism
Rapid progress in fertility preservation strategies has led to the investigation of ways in which fertile gametes could be generated from cryopreserved immature testicular tissue. Childhood cancer patients remain the major group that can benefit from these techniques. Other potential candidates include patients undergoing gonadectomy and patients with Klinefelter's syndrome and cryptorchid testes. This review aims to present an overview of the current state of knowledge in experimental germ cell transplantation, testicular tissue transplantation, and germ cell culture as fertility preservation methods for males. We included English articles published in PubMed as well as personal files with the focus on studies including human or nonhuman material. Germ cell and testicular tissue transplantation demonstrate clinical options to mature germ cells from immature primate testicular tissue. The most promising approach involves autologous grafting of immature testicular tissue, whereas germ cell maturation in vitro provides the best strategies to overcome problems of cancer contamination in cryopreserved testicular tissue. Three-dimensional and organ culture systems offer the possibility to differentiate immature male germ cells up to the stage of elongated spermatids. Further characterization of early germ cell development in humans is needed to modify these systems for clinical use.